SCHEMBL1543883

SCHEMBL1543883

COc1c(C=Cc2ccccc2C#N)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
MCL1 Q07820 2/20 0.38
AR P10275 2/20 0.34
PGR P06401 1/20 0.34
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
GAA P10253 3/20 0.32
GLA P06280 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TNFRSF1A P19438 1/20 0.32
CHEK1 O14757 1/20 0.31
ACMSD Q8TDX5 2/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
GALR3 O60755 1/20 0.30
HPGD P15428 1/20 0.30
MAPK14 Q16539 1/20 0.30
CREBBP Q92793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543881 1.00 CYP3A4 (0.61) CYP3A4MCL1ARPGREGFR
SCHEMBL1542485 0.88 CYP3A4 (0.56) CYP3A4MCL1KDM4EPDE3BPDE3A
SCHEMBL2128630 0.88 CYP3A4 (0.56) CYP3A4MCL1KDM4EPDE3BPDE3A
SCHEMBL12678795 0.85 CYP3A4 (0.66) CYP3A4EGFRERBB2TNFRSF1A
SCHEMBL1542386 0.85 CYP3A4 (0.64) CYP3A4EGFRERBB2TNFRSF1AACMSD
SCHEMBL1542383 0.85 CYP3A4 (0.64) CYP3A4EGFRERBB2TNFRSF1AACMSD
SCHEMBL1764330 0.85 CYP3A4 (0.74) CYP3A4EGFRERBB2TNFRSF1A
SCHEMBL1764331 0.85 CYP3A4 (0.74) CYP3A4EGFRERBB2TNFRSF1A
SCHEMBL2128218 0.84 CYP3A4 (0.76) CYP3A4ARPGR
SCHEMBL2128220 0.84 CYP3A4 (0.76) CYP3A4ARPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885MCL1 2118/4885AR 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.